HTBX Heat Biologics Inc

Price (delayed)

$7.2

Market cap

$181.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.31

Enterprise value

$152.28M

Highlights
The EPS has soared by 65% YoY and by 20% from the previous quarter
The quick ratio has grown by 42% from the previous quarter
Heat Biologics's net income has decreased by 33% YoY and by 4.8% from the previous quarter
The revenue has contracted by 20% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of HTBX
Market
Shares outstanding
25.25M
Market cap
$181.82M
Enterprise value
$152.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.33
Price to sales (P/S)
67.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.92
Earnings
Revenue
$2.58M
EBIT
-$27.29M
EBITDA
-$26.83M
Free cash flow
-$21.76M
Per share
EPS
-$1.31
Free cash flow per share
-$0.9
Book value per share
$5.4
Revenue per share
$0.11
TBVPS
$5.91
Balance sheet
Total assets
$144.47M
Total liabilities
$8.01M
Debt
$1.76M
Equity
$137.3M
Working capital
$130.83M
Liquidity
Debt to equity
0.01
Current ratio
43.95
Quick ratio
43.43
Net debt/EBITDA
1.1
Margins
EBITDA margin
-1,038%
Gross margin
100%
Net margin
-1,055.8%
Operating margin
-1,060.4%
Efficiency
Return on assets
-23.9%
Return on equity
-25.8%
Return on invested capital
-30.9%
Return on capital employed
-19.3%
Return on sales
-1,055.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HTBX stock price

How has the Heat Biologics stock price performed over time
Intraday
2.13%
1 week
-5.76%
1 month
12.5%
1 year
30.67%
YTD
34.33%
QTD
-1.1%

Financial performance

How have Heat Biologics's revenue and profit performed over time
Revenue
$2.58M
Gross profit
$2.58M
Operating income
-$27.41M
Net income
-$27.29M
Gross margin
100%
Net margin
-1,055.8%
The company's operating margin has shrunk by 77% YoY and by 25% QoQ
The net margin has dropped by 67% year-on-year and by 19% since the previous quarter
The operating income has declined by 41% year-on-year and by 10% since the previous quarter
Heat Biologics's net income has decreased by 33% YoY and by 4.8% from the previous quarter

Growth

What is Heat Biologics's growth rate over time

Valuation

What is Heat Biologics stock price valuation
P/E
N/A
P/B
1.33
P/S
67.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.92
The EPS has soared by 65% YoY and by 20% from the previous quarter
The P/B is 26% below the 5-year quarterly average of 1.8 and 5% below the last 4 quarters average of 1.4
Heat Biologics's equity has increased by 18% QoQ
HTBX's price to sales (P/S) is 152% more than its 5-year quarterly average of 26.8 and 69% more than its last 4 quarters average of 39.9
The revenue has contracted by 20% YoY and by 12% from the previous quarter

Efficiency

How efficient is Heat Biologics business performance
HTBX's return on invested capital has surged by 86% year-on-year and by 25% since the previous quarter
The company's return on equity has surged by 75% YoY and by 23% QoQ
The ROS has plunged by 67% YoY and by 19% from the previous quarter
The ROA has soared by 66% YoY and by 20% from the previous quarter

Dividends

What is HTBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HTBX.

Financial health

How did Heat Biologics financials performed over time
The quick ratio has grown by 42% from the previous quarter
The current ratio is up by 41% since the previous quarter
The debt is 99% smaller than the equity
The debt to equity has dropped by 88% year-on-year and by 50% since the previous quarter
Heat Biologics's equity has increased by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.